scholarly journals Fabrication of 3D-Printed Fish-Gelatin-Based Polymer Hydrogel Patches for Local Delivery of PEGylated Liposomal Doxorubicin

Marine Drugs ◽  
2020 ◽  
Vol 18 (6) ◽  
pp. 325
Author(s):  
Jin Liu ◽  
Tatsuaki Tagami ◽  
Tetsuya Ozeki
Keyword(s):  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Fish Gelatin ◽  
Low Viscosity ◽  
Uv Led ◽  
Particle Size Increase ◽  
Carboxymethyl Cellulose Sodium ◽  
3D Printed ◽  
Semi Solid ◽  
Main Component

3D printing technology has been applied to various fields and its medical applications are expanding. Here, we fabricated implantable 3D bio-printed hydrogel patches containing a nanomedicine as a future tailored cancer treatment. The patches were prepared using a semi-solid extrusion-type 3D bioprinter, a hydrogel-based printer ink, and UV-LED exposure. We focused on the composition of the printer ink and semi-synthesized fish gelatin methacryloyl (F-GelMA), derived from cold fish gelatin, as the main component. The low viscosity of F-GelMA due to its low melting point was remarkably improved by the addition of carboxymethyl cellulose sodium (CMC), a pharmaceutical excipient. PEGylated liposomal doxorubicin (DOX), as a model nanomedicine, was incorporated into the hydrogel and liposome stability after photo-polymerization was evaluated. The addition of CMC inhibited particle size increase. Three types of 3D-designed patches (cylinder, torus, gridlines) were produced using a 3D bioprinter. Drug release was dependent on the shape of the 3D-printed patches and UV-LED exposure time. The current study provides useful information for the preparation of 3D printed nanomedicine-based objects.

Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients

2013 ◽  
Vol 9 (1) ◽  
pp. 1-7
Author(s):  
Alessandra Romano ◽  
Giuseppina Uccello ◽  
Paolo Spina ◽  
Rosario Cunsolo ◽  
Calogero Vetro ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Salvage Chemotherapy

scholarly journals Late-Maturity Alpha-Amylase in Wheat (Triticum aestivum) and Its Impact on Fresh White Sauce Qualities

Foods ◽  
2021 ◽  
Vol 10 (2) ◽  
pp. 201
Author(s):  
Galex K. S. Neoh ◽  
Mark J. Dieters ◽  
Keyu Tao ◽  
Glen P. Fox ◽  
Phuong T. M. Nguyen ◽  
...  
Keyword(s):  
Grain Filling ◽  
Drastic Reduction ◽  
Product Usage ◽  
Low Viscosity ◽  
Pasting Characteristics ◽  
Late Maturity ◽  
Semi Solid ◽  
New Applications ◽  
White Sauce

When wheat experiences a cold-temperature ‘shock’ during the late stage of grain filling, it triggers the abnormal synthesis of late-maturity α-amylase (LMA). This increases the enzyme content in affected grain, which can lead to a drastic reduction in falling number (FN). By commercial standards, a low FN is taken as an indication of inferior quality, deemed unsuitable for end-product usage. Hence, LMA-affected grains are either rejected or downgraded to feed grade at the grain receiving point. However, previous studies have found no substantial correlation between low FN-LMA and bread quality. The present study extends previous investigations to semi-solid food, evaluating the physical quality of fresh white sauce processed from LMA-affected flour. Results show that high-LMA flours had low FNs and exhibited poor pasting characteristics. However, gelation occurred in the presence of other components during fresh white sauce processing. This demonstrates that LMA-affected flours may have new applications in low-viscosity products.

scholarly journals A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer

2021 ◽  
Author(s):  
Shunji Takahashi ◽  
Munetaka Takekuma ◽  
Kenji Tamura ◽  
Kazuhiro Takehara ◽  
Hiroyuki Nomura ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase I ◽  
Liposomal Doxorubicin ◽  
Advanced Ovarian Cancer ◽  
Pegylated Liposomal Doxorubicin ◽  
Japanese Patients ◽  
Pharmacokinetic Analysis ◽  
Dependent Manner ◽  
Drug Concentrations ◽  
Grade 3

Abstract Background Advanced relapsed ovarian cancer has a poor prognosis, and treatment options are limited. Methods This phase I trial investigated the dosage, safety, pharmacokinetics and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in Japanese patients with advanced relapsed ovarian, fallopian tube, or primary peritoneal cancer. Patients received trabectedin 0.9 or 1.1 mg/m2 immediately after PLD 30 mg/m2; both drugs were given by intravenous infusion. Treatment was repeated every 21 days until disease progression or unacceptable toxicity. The maximum tolerated dose (MTD) was determined in an initial dose escalation phase, and this was used in a subsequent safety assessment phase. Safety and tumor response were monitored throughout the trial, and drug concentrations for pharmacokinetic analysis were measured during cycle 1. Results Eighteen patients were included. The MTD of trabectedin was determined as 1.1 mg/m2. Gastrointestinal adverse events were experienced by all patients, but were mostly grade 1 or 2 in intensity. Most patients had grade ≥ 3 elevations in transaminase levels or grade ≥ 3 reductions in neutrophil count, but these events were generally manageable through dose reduction and/or supportive therapies, as appropriate. There were no deaths during the trial. Trabectedin exposure increased in a dose-dependent manner. The overall response rate was 27.8%. Conclusions Trabectedin, in combination with PLD, may have clinical benefits in Japanese patients with relapsed advanced ovarian cancer. The recommended dosage of trabectedin for further study in this population is 1.1 mg/m2 once every 21 days. Clinical trial registration number: JapicCTI-163164

Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma

2007 ◽  
Vol 46 (2) ◽  
pp. 230-233 ◽  
Author(s):  
Pehr A. Lind ◽  
Gisela Naucler ◽  
Agneta Holm ◽  
Michael Gubanski ◽  
Christer Svensson
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Advanced Hepatocellular Carcinoma

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan

2006 ◽  
Vol 103 (1) ◽  
pp. 212-218 ◽  
Author(s):  
Gabrielle Gossner ◽  
Robert L. Coleman ◽  
David G. Mutch ◽  
Neil S. Horowitz ◽  
Janet S. Rader ◽  
...  
Keyword(s):  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Ca 125 ◽  
Primary Peritoneal Cancer ◽  
Peritoneal Cancer
Sign in / Sign up

Export Citation Format

Share Document